GREATER FLEXIBILITY IN MEDICINE SAFETY PROGRAMS DELIVERED BY PHARMACISTS Advocacy leads to Home Medicines Reviews and Residential Medication Management Reviews by telehealth
With
Brooke Shelly FPS, Board Director & PSA Strategic Agreements Lead
Pharmaceutical Society of Australia (PSA)
SEGMENT
Filmed in Sydney | August 2026
Addressing delegates at PSA26, the Pharmaceutical Society of Australia’s (PSA) yearly conference, the Minister for Health and Ageing, the Hon. Mark Butler MP, announced negotiations are progressing on the First Pharmacy Programs Agreement (1PPA), and that from 1 November, follow-up services for Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) programs will be able to be delivered via telehealth.
PSA National President, Professor Mark Naunton MPS, welcomed the announcement, declaring it an important step in modernising pharmacist-delivered care and improving patient access to medication safety programs, particularly for those in rural and remote Australia who may have limited access to healthcare.
Brooke Shelly FPS, PSA Strategic Agreements Lead and Board Director, spoke with Australian Health Journal, stating the announcement was an important step forward for the profession, with the ability for pharmacists to now use telehealth for follow ups aligning medicines safety programs more closely with other sectors of the health system.
“This reform reflects years of hard-fought advocacy from PSA and demonstrates what can be achieved when government and the profession work together with a shared focus on better patient outcomes,” Ms Shelly said.
“Medicines safety is fundamental to a stronger, safer health system. While we’re pleased to have greater flexibility in how these programs are delivered, there is still more to achieve, and today’s announcement provides a strong foundation for the work to come.
The announcement reflects the success of sustained advocacy by PSA and its members, together with constructive engagement with the Australian Government. PSA remains committed to working collaboratively with Government to progress the 1PPA.
Brooke Shelly FPS is a rural Victorian pharmacist with a dynamic portfolio career spanning General Practice, credentialed medication management and residential medication management reviews, and multidisciplinary telehealth. She is a GP Pharmacist at Ontario Medical Clinic, a Senior Clinical Pharmacist with Beyond Pain, and the sole proprietor of MyMedManagement, delivering complex medication and residential medication management reviews across regional and remote areas.
Source: Adapted from PSA media release, July 2026
-
Role of milk in cognitive function and quality of life in older adults
New research emphasises the role of cows’ milk, particularly A1 protein free milk, in enhancing cognitive function and quality of life for older adults with mild cognitive impairment (MCI). A multi-centre, double-blinded, randomised controlled clinical study published in *The Journal of Nutrition, Health and Aging* evaluated 88 milk-tolerant Chinese adults aged 65-75 over three months. Participants consumed either ordinary skim milk or A1 protein free skim milk, leading to improvements in various cognitive assessments.
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
